Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HA1 | P13674 | 1/20 | 0.32 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | CASP6 | P55212 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1070654 | 0.80 | CCR1 (0.46) | P4HA1P4HTMCCR1CCR5CCR8 | |
| SCHEMBL30958843 | 0.80 | CCR1 (0.46) | P4HA1P4HTMCCR1CCR5CCR8 | |
| SCHEMBL17729305 | 0.76 | CA12 (0.38) | CCR1CCR5CCR8HDAC6SCN9A | |
| SCHEMBL1186172 | 0.75 | ESR1 (0.46) | SCN9AHSD17B1HSD17B2HDAC4ESR1 | |
| SCHEMBL27584154 | 0.72 | PTGER4 (0.38) | CCR1CCR5CCR8HDAC6 | |
| SCHEMBL17729402 | 0.71 | PTPN1 (0.42) | P4HA1P4HTMHDAC4FAAH | |
| SCHEMBL852125 | 0.71 | FYN (0.46) | HSD17B1HSD17B2KDM1A | |
| SCHEMBL657438 | 0.71 | TYR (0.43) | F2RL1ESR1CASP6 | |
| SCHEMBL16159214 | 0.69 | SCN9A (0.36) | SCN9AHSD17B1HSD17B2HDAC4 | |
| SCHEMBL24302699 | 0.68 | ALDH1A1 (0.52) | P4HA1P4HTMCCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810969-B1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | MSD KK (JP) | 2013-08-07 | — | — | EP | disclosed |
| CN-101094847-B | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-7932394-B2 | 1-{[5-[4-(Methylsulfonyl)phenoxy]-2-(2-pyridinyl)-1H-benzimidazol-6-yl]methyl}-5-thioxo-2-pyrrolidinone;glucokinase activator; antidiabetic agents; obesity; prevention of retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis; antiischemic agents; cardiotonic agents | MSD K.K. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1810969-A1 | ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125429-A1 | Aryloxy-Substituted Benzimidazole Derivatives | GCK, GCKR, SLC5A1 | P4HA1 3130/4885P4HTM 4521/4885CCR1 2431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.